Biogen (NASDAQ: BIIB) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Insider & Institutional Ownership

87.8% of Biogen shares are owned by institutional investors. Comparatively, 64.2% of Syndax Pharmaceuticals shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 24.1% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


This table compares Biogen and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biogen 29.44% 38.51% 20.80%
Syndax Pharmaceuticals -4,304.34% -57.90% -45.09%

Risk & Volatility

Biogen has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 4.43, suggesting that its share price is 343% more volatile than the S&P 500.

Earnings and Valuation

This table compares Biogen and Syndax Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Biogen $11.45 billion 5.73 $3.70 billion $16.31 19.03
Syndax Pharmaceuticals $1.22 million 202.12 -$44.47 million ($2.68) -3.77

Biogen has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Biogen and Syndax Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen 0 10 17 1 2.68
Syndax Pharmaceuticals 0 0 8 0 3.00

Biogen currently has a consensus target price of $342.62, indicating a potential upside of 10.36%. Syndax Pharmaceuticals has a consensus target price of $24.29, indicating a potential upside of 140.21%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Biogen.


Biogen beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Biogen

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.